

Evonik continues to optimize its global production setup for MetAMINO®

- Further technical measures planned at Evonik's methionine production sites in Singapore and Antwerp
- Focus on catalyst exchange, energy efficiency and sustainability
- Measures require a shutdown of production facilities for 6–7 weeks in Q3/Q4

Essen, Germany. Evonik will continue to optimize its global methionine production setup for MetAMINO® (DL-methionine) in the third and fourth quarter of 2025. Implementation of several technical measures requires a shutdown of the production facilities for methionine and its precursors for 6–7 weeks each at Evonik's Singapore site in August/September and at its Antwerp site in September/October 2025.

In Singapore, the maintenance schedule of a raw material supplier necessitates an early shutdown in Q3. Evonik will synchronize this with the catalyst exchange in its methionine production and take this opportunity to further improve the energy efficiency and CO₂ emissions of the plant.

In Antwerp, Evonik will also combine a catalyst exchange with the continuation of the measures begun in May to reduce nitrogen, sulphur, and CO₂ emissions. During the shutdown of the methionine facilities for 6–7 weeks in September and October, Evonik Antwerp site operations will implement further milestones from its climate roadmap and make the site's utilities infrastructure fit for the future. These upgrades are major enablers contributing to further reductions in the carbon footprint of Evonik's production facilities.

“With our global production setup for MetAMINO® we continue to ensure supply security for our customers worldwide for the years to come. MetAMINO® also has a product carbon footprint that is approximately 35 percent lower than the calculated global industry average*. This is the result of our constant efforts to

June 4, 2025

Main press contact

Anastasia Noryk
Head of Market Communications
Animal Nutrition
anastasia.noryk@evonik.com

Alternative press contact

Dr. Jürgen Krauter
Head of Market Communications
Evonik
juergen.krauter@evonik.com

Evonik Industries AG

Rellinghauser Straße 1–11
45128 Essen
Germany
Phone +49 201 177–01
Fax +49 201 177–3475
www.evonik.com

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Lauren Kjeldsen, Dr. Claudine Mollenkopf,
Maïke Schuh, Thomas Wessel

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

optimize our assets”, said Dr. Dirk Hoehler, head of the amino acids business of Evonik’s Animal Nutrition business line.

MetAMINO® is used in livestock production to feed animals healthily, efficiently, and sustainably. With its science-based approach, the Animal Nutrition business line of Evonik develops products, services and system solutions that help supply a growing world population with healthy, high-quality and affordable animal protein.

*Methodology for global industry average excluding Evonik: estimated internally by Evonik’s market intelligence, technology and lifecycle assessment experts. Industry methionine sources include DL-methionine, L-methionine and methionine hydroxy analogue (MHA). Global Warming Potential is estimated accounting for the higher bioavailability of methionine in MetAMINO® versus MHA.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.2 billion and an operating profit (adjusted EBITDA) of €2.1 billion in 2024. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. About 32,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Advanced Technologies

The Advanced Technologies segment includes Evonik’s market-leading businesses that leverage technological expertise and process know-how. These businesses feature high-performance polymers and crosslinking agents, hydrogen peroxide and silica, as well as feed ingredients. In 2024, the segment generated sales of €6.1 billion with around 8,000 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.